Johnson & Johnson (JNJ) stock

Medicines and medtech , market cap $656B

Medicines and medtech

Worth $656B

Pre-market

$277.86

+0.59%

Close $276.22 +1.43%

As of 8:26 AM ET pre-market, delayed 15+ min · Live for Pro members

Quality Score

Excellent

In its industry

#5of 90

Pharma

Checks firing

5of 14

Trending up

From 52-week high

-2.1%

under its best in a year

JNJ's Quality Score was unchanged on Fri, Nov 6, at 16.

Follow JNJ's trial news. Pro members can get an alert when Johnson & Johnson files news, and see its trials, share raises, and its CEO's filings.

Get an alert when JNJ files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextDec 15, 2026 · In 36 daysPhase 3 main data due · ClinicalTrials.gov · Nov 3

Why JNJ fell on Oct 13

Down 6% on Oct 13 while the S&P 500 was flat.

Its Oct 13 results: net earnings were $210M, from $5.15B a year before; earnings per share were $0.09, from $2.12. It fell 6% on Oct 13.

Sources: Price history, Oct 13, 2026; Company release, Oct 13, 2026

1 more reason, free with an account →2 more reasons why JNJ fell on Oct 13, from its filings, with the other side, the timeline, and its peers, for Pro members.

Why JNJ still beats the market over a year

Up 51% over the year to Nov 6 while the S&P 500 rose 11%; down 6% on Oct 13.

3 reasons, from its filings, with the timeline, for Pro members.

Key facts on JNJ

Key facts on JNJ
Profit margin	29%, up from 22% in 3 years
Latest filing	10-Q, Oct 21 Filed its quarterly report (10-Q) for the quarter to Sep 27, 2026

1 more reason behind JNJ's 16, free with an account →3 more reasons behind JNJ's 16, for Pro members.

JNJ in the news

Big story

Guidance

Johnson & Johnson beats estimates, raises 2026 guidance

JNJ closed +0.9% that day.

Reported by Investing.com · covered by 9 outlets

Get an alert on JNJ's next big story →

Outlet counts from the GDELT Project. The move is what JNJ did that session, not a claim about why.

What's next

Reports Tue Jan 26, before the open

After its last 4 reports it closed -1.9% on average, higher 1 of 4 times.

JNJ catalysts

Coming up

5 more coming up and 23 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for JNJ

Next Phase 3 data on the registry

Dec 15In 36 daysPhase 3 main data due for Nipocalimab, Dec 15, 2026Phase 3 main data due · ClinicalTrials.gov · Nov 3

What it means: the date the registry lists for the trial’s last main measurement, as the sponsor estimates it. Results usually follow weeks to months later.

Lead program: Nipocalimab
Another trial: PROTEUSPhase 3 · Active · 2,517 people · main data estimated Dec 1, 2026 · NCT03767244

161 more trials, 11 with data due this year, 40 drugs past Phase 1 and 35 filings, for Pro members.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 11, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

EVP, WW Chair, MedTech Timothy Schmid sold 33,597 shares on Sep 2. 14 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Joaquin Duato buys or sells

For Pro members: every trade, and Joaquin Duato’s 13 filings and quotes.

Get an alert when JNJ files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 13 daysFDA decisionIn 13 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 13 daysFDA decisionIn 13 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 43 daysFDA decisionIn 43 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why JNJ scores 16

Excellentfor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

Well above its recent run. JNJ scores 16 today, against a median of 11 over its last 20 recorded sessions.

+5Chart checks 5 of 14 firing right now, one point each
+4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high

Size adds
Profit addsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Persistence adds
News adds

No effect today: Run-up, Growth, Dilution, Volatility, Cash flow, and Insider trades.

What every line is worth, and the reason behind it, on JNJ and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:26 AM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when JNJ's Quality Score turns up

A free account. No card.

How JNJ ranks in Pharma

JNJ is #5 of 90 by Quality Score.

How JNJ ranks in Pharma
Rank	Stock	Checks	Quality Score
1	ABBVAbbVie	8/14	24
2	LLYEli Lilly	5/14	18
3	CRONCronos	5/14	18
	INVAInnoviva		Open for its score
	IRDOpus Genetics		Open for its score
	KARDKardigan		Open for its score
5	JNJJohnson & Johnson	5/14	16

Net income over four quarters: JNJ $16.1B, BMY $9.24B.

When does JNJ report earnings, and what happens after?

Reports Tue Jan 26, before the open (in 78 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What JNJ reported on Oct 13, 2026

The quarter

Sales of $25.4B; a profit of $0.09 a share.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By segment
Innovative Medicineup 7.7%	$17B66%	$16B65%	$16B65%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 21)

6 more lines, for Pro members.

The outlook

No outlook figures read from this release.

The numbers

Market value: $656B; today
Sales: $99B; up 7.8% on the year
Free cash flow: $21B; last 12 months

Sales grew 2.7% a year over 5 years, fiscal 2020 to 2025.

Pays $5.36 a share a year.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on JNJ: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+0.9%-2.7%-5.7%

Apr 14Jul 15Oct 13

Reported	When	Gap	Reaction	5 days
Oct 13, 2026Before open	Before open	-3.5%	-5.7%	-3.8%
Jul 15, 2026Before open	Before open	-1.5%	-2.7%	-1.3%
Apr 14, 2026Before open	Before open	-1.2%	+0.9%	-3.1%

JNJ closed higher after 1 of its last 4 reports.

All 4 reports, and JNJ's Quality Score going into each

JNJ sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to $94B in 2025. It made a profit in each of the eight years.

JNJ has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on JNJ, and all 14 on every stock.Get in free →

JNJ RSI on Nov 6: 59.4, above its 50-day and 200-day averages

Not scored

RSI 59.4, MACD above signal, above both averages. Not scored.13 readings

The deep dive on JNJ

What it does and how it makes money4 findingsIt kept 35 cents of each dollar of sales in fiscal 2025: $32.6B of profit before tax on $94.2B of sales.Annual report, filed Feb 11, 2026"Beginning in September 2025, Actelion Pharmaceuticals Ltd, Actelion Pharmaceuticals US, Inc. …" (10-K for fiscal 2025)SEC filing · Feb 11, 2026
Where it stands4 findingsFor Pro members4 findings on where JNJ stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"In February 2026 …" (10-Q for the quarter to Sep 27, 2026)SEC filing · Oct 21, 2026Completed its acquisition of Halda Therapeutics on Dec 26, 2025, for $3.05 billion in total purchase consideration.SEC filing · Feb 11, 2026One wholesaler made up 22% of its revenue in fiscal 2025, up from 20% in fiscal 2024.SEC filing · Feb 11, 2026
Who holds and trades it4 findingsFor Pro members4 findings on who holds and trades JNJ, for Pro members
Against its closest peers1 peerNet income over four quarters: JNJ $16.1B, BMY $9.24B.

12 more findings on JNJ, each with its source, for Pro members.

JNJ share count over time

Shares: about the same count as a year ago (to Sep 27).

Shares of JNJ outstanding, as filed
Shares outstanding	As of
2.41B	Oct 15, 2026
2.41B	Jul 17, 2026
2.41B	Apr 17, 2026
2.41B	Feb 6, 2026

Offerings, shelves, and splits of JNJ, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Feb 11, 2026

Is JNJ's dividend covered? What its financials say

Its dividends come to 64% of its free cash flow.

JNJ's dividend against its free cash flow
Dividend	$5.36 a share a year Paid 4 times a year
Paid out	About $13B a year $5.36 a share on 2.4B shares, its average count in the quarter to Sep 27, 2026
Free cash flow	$21B The last four quarters, to Sep 27, 2026
Record	Raised every year since 2007 Its dividends a share each year, from its annual reports

JNJ insider trades

6 insiders sold $70.2M across 11 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellTimothy Schmid$6.2MEVP, WW Chair, MedTechat $274.74 on Sep 2, filed Sep 4

SellTimothy SchmidEVP, WW Chair, MedTech$6.2Mat $274.74 on Sep 2, filed Sep 4

All 11 insider filings on JNJ from the last six months, for Pro members.

All JNJ insider trades

JNJ trades by Congress and the executive branch

31 trades disclosed in the last six months. The newest:

SellThomas Kean$1K to $15KHousetraded Sep 30, disclosed Oct 30(30 days later)

SellThomas KeanHouse$1K to $15Ktraded Sep 30, disclosed Oct 30(30 days later)

All 31 trades on JNJ disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

JNJ's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Joaquin DuatoCEO and Chairman of the Board · 6 trades
Joseph J. WolkExec VP, CFO · 4 trades
Timothy SchmidEVP, WW Chair, MedTech · 5 trades
James D. SwansonEVP, CIO · 3 trades
John C. ReedEVP, Innovative Medicine, R&D · 3 trades
Elizabeth ForminardEVP, Chief Legal Officer · 2 trades
Vanessa BroadhurstEVP, Global Corp Affairs · 2 trades
Jennifer L. TaubertEVP, WWC. Innovative Medicine · 1 trade

5 more officers and directors file at JNJ.

See insider trades by person

Which ETFs hold JNJ?

In ETFs: JNJ is 5.7% of SPMO, 3.2% of DGRO, and 2.8% of VIG, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jul 31 to Aug 31, 2026.

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

140,800 employeesNew Brunswick, NJjnj.com

What Johnson & Johnson says it competes with

“In all of their product lines, the Company's subsidiaries compete with companies both locally and globally.”

From its annual report, SEC filing · Feb 11, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on JNJ and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move JNJ's score: 5 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayOct 7Ro Khanna bought JNJ$1K to $15K, disclosed Oct 7

Alerts are optional.

See JNJ's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 9, 2026: JNJ's Quality Score is 16 (Excellent), #5 of 90 in Pharma. Insiders sold $70.2M in the last 6 months (Form 4).

What does JNJ's Quality Score say?

JNJ scores 16 today, which Breakaway calls Excellent. It is #5 of 90 in Pharma by Quality Score, with 5 of 14 chart checks firing. Down 6% on Oct 13 while the S&P 500 was flat. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is JNJ's Quality Score?

JNJ scores 16 today, which Breakaway calls Excellent (15 to 19). That is #5 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind JNJ's 16.

Are insiders buying JNJ?

6 insiders sold $70.2M across 11 filings in the last 6 months. No open-⁠market buys on record. The newest is Timothy Schmid, EVP, WW Chair, MedTech, who sold $6.2M on Sep 2. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.